cc-94676
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 19, 2020 (NCT04428788)
Timeline
Indications
Mechanism of action
- Androgen ReceptorDEGRADER
AR degrader
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095270 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07242781 | Phase 1 | Dec 8, 2025 | Bristol-Myers Squibb, Celgene |
| NCT06764485 | Phase 3 | Mar 13, 2025 | Bristol-Myers Squibb, Celgene |
| NCT06433505 | Phase 1 | May 30, 2024 | Bristol-Myers Squibb, Celgene |
| NCT06417229 | Phase 1 | May 28, 2024 | Bristol-Myers Squibb, Celgene |
| NCT04428788 | Phase 1 | Jun 19, 2020 | Celgene |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 5 | 5 | 2 | 2020 |
| Bristol-Myers Squibb | For profit | 4 | 0 | 2 | 2024 |
2 organizations
Page 1 / 1